Background: Eosinophil infiltration of bronchial tissues and subsequent release of inflammatory mediators by them are the hallmarks of bronchial asthma but it has not yet been clarified whether anti-asthma drugs affect these cells directly. In this study, we investigated the direct effects of 8 clinically used anti-asthma drugs [salbutamol, salmeterol, theophylline, denbufylline, disodium cromoglycate (DSCG), azelastine, ketotifen and dexamethasone] on superoxide anions (O–2) and eosinophil peroxidase (EPO) release from human blood eosinophils in vitro. Methods: Highly purified eosinophils were stimulated for O–2 release with platelet-activating factor (PAF) or interleukin-5 (IL-5), while for EPO release complement fragment (C5a) or N-formyl-methionyl-leucyl-phenylalanine (FMLP) was employed. Generated products were assayed by standard techniques. Results: All the drugs, except ketotifen and dexamethasone, inhibited PAF-induced O–2 release in a dose-dependent manner. The IC50 values were 0.7, 5.8, 330, 3,500, 4,200 and 6,250 nM for DSCG, denbufylline, salmeterol, azelastine, salbutamol and theophylline, respectively. On IL-5-induced release, the effects were similar except that salbutamol completely failed to inhibit the release induced by this stimulus. In contrast, EPO release was generally poorly inhibited, especially when the release was induced by C5a. Only theophylline and azelastine (both at 10–4 M or more) were able to inhibit EPO release by both C5a and FMLP. Salbutamol and, to a lesser extent, salmeterol inhibited FMLP-, but not C5a-induced EPO release, while all the other drugs tested were inactive. Conclusions: The results show that some of the anti-asthma drugs, but not all, do exert direct effects on human blood eosinophils but these effects may be stimulus-dependent and by far more pronounced against O–2 release than against degranulation.

Keywords:
Eosinophils, Anti-asthma drugs, Superoxide anions, Degranulation, Asthma
1.
Frigas E, Gleich GJ: The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986;77:527–537.
2.
Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB: Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Am Rev Respir Dis 1988;137:62–69.
3.
Barnes PJ: New concepts in pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol 1989;83:1013–1026.
4.
Motijima S, Frigas E, Loegering DA, Gleich GT: Toxicity of eosinophil proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989;139:801–805.
5.
Laitinen LA, Heins M, Laitinen A, Kava T, Haahtela T: Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985;131:599–606.
6.
Braun RK, Franchini M, Erard F, Rihs S, De Vries IJM, Blaser K, Hansel TT, Walker C: Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. Eur J Immunol 1993;23:956–960.
7.
Martin LB, Kita H, Leiferman KM, Gleich GJ: Eosinophils in allergy: Role in disease, degranulation and cytokines. Int Arch Allergy Immunol 1996;109:207–215.
8.
Pedersen B, Dahl R, Larsen BB, Venge P: The effect of salmeterol on the early and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein and serum eosinophils protein X. Allergy 1993;48:377–382.
9.
Di Lorenzo G, Morici G, Norrito F, Mansueto P, Melluso M, D’ambrosio PF, Sangiorgi GB: Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Clin Exp Allergy 1995;25:951–956.
10.
Anderson GP: Pharmacology of formoterol: An innovative bronchodilator; in Anderson GP, Chapman ID, Morley J (eds): in Agents and Actions Supplements. Basel, Birkhäuser, 1991, vol 34: New Drugs for Asthma Therapy, pp 97–115.
11.
Rabe KF, Giembycz MA, Dent G, Perkins RS, Evans P, Barnes PJ: Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol 1993;231:305–308.
12.
Sanjar S, McCabe PR, Reynolds LH: Salmeterol, a long acting beta-2 agonist, inhibits antigen-induced bronchial eosinophil accumulation. Am Rev Respir Dis 1991;143:A755.
13.
Beaven MA, Maeyama K, Wolde-Mussie E, Lo TN, Ali H, Cunha-Melo JR: Mechanism of signal transduction in mast cells and basophils: Studies with RBL-2H3 cells. Agents Actions 1987;20:137–145.
14.
Shute J: Signal transduction mechanisms in human eosinophils. Clin Exp Allergy 1993;23:713–717.
15.
Hansel TT, De Vries IJM, Iff T, Ris S, Wandzilak M, Betz S, Blaser K, Walker C: An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145:105–110.
16.
Sedgwick JB, Vrtis RF, Gourley MF, Busse WW: Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J Allergy Clin Immunol 1988;81:876–883.
17.
Kroegel C, Yukawa T, Dent G, Venge P, Chung KF, Barnes PJ: Stimulation of degranulation from eosinophils by platelet activating factor. J Immunol 1989;142:3518–3526.
18.
Munoz NM, Rabe KF, Vita AJ, McAllister K, Mayer D, Weiss M, Leff AR: Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. J Pharmacol Exp Ther 1995;273:850–854.
19.
Bach MK, Brashler JR, Petzold EN, Sanders ME: Superoxide production by human eosinophils can be inhibited in an agonist-dependent manner. Agents Actions 1992;35:1–11.
20.
van der Bruggen T, Kok PTM, Raaijmakers JAM, Verhoeven AJ, Kessels RGC, Lammers JWJ, Koenderman L: Cytokine priming of respiratory burst in human eosinophils is calcium independent and accompanied by induction of tyrosine kinase activity. J Leukoc Biol 1993;53:347–353.
21.
Giembycz MA: Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 1992;43:2041–2051.
22.
Hatzelmann A, Tenor H, Schudt C: Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995;114:821–831.
23.
Church MK, Young KO: The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol 1983;78:671–679.
24.
Butchers PR, Vardey CJ, Johnson M: Salmeterol, a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991;104:672–676.
25.
Sedgwick JB, Calhoun WJ, Vrtis RF, Bates ME, McAllister PK, Busse WW: Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 1992;149:3710–3718.
26.
Zeck-Kapp G, Kroegel C, Riede UN, Kapp A: Mechanism of human eosinophil activation by complement protein C5a and PAF: Similar functional responses are accompanied by different morphologic alterations. Allergy 1995;50:43–47.
27.
Gleich GJ, Adolphson CR: The eosinophil leukocyte: Structure and function. Adv Immunol 1986;39:177–253.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.